Skip to content

Source filing unavailable

Q2 2024 · —
Revenue—
Net Income-$17.05MN/M vs Q2 2023N/M vs Q1 2024
EPS Diluted-$19.01no prior Q2 2023 on fileN/M vs Q1 2024
Operating Income-$19,750,000—
Operating Cash Flowderived-$12,908,000—
Free Cash Flowderived-$12,927,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ2 2024Q2 2023
Net Income-$17.05M-$9.29M
EPS Diluted-$19.01—

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Bicara Therapeutics Inc. · CIK 2023658 · Engraved from SEC EDGAR